Amphetamines were widely used to treat patients with post-encephalitic Parkinsonism in the 1930s (Finkelman and Shapiro, 1937; Davis and Stewart, 1938) . Subjective improvement in mood and energy was often considerable, with reversal of disordered sleep rhythms, but there was little or no objective improvement in the symptoms of Parkinsonism. Rigidity was sometimes slightly lessened, but akinesia and tremor were not altered. The total reduction in disability was probably less than that obtained from anticholinergic drugs (Solomon et al., 1937) . Amphetamines, however, had a dramatic effect on the oculogyric crises of post-encephalitic Parkinsonism, which were often abolished (Davis and Stewart, 1938; Matthews, 1938) . There was no evidence that patients with postencephalitic Parkinsonism developed tolerance or became addicted to amphetamines (Solomon et al., 1937) , but because of the very slight therapeutic effect, and the possibility of drug misuse, these compounds have rarely been used in the treatment of idiopathic paralysis agitans (Calne and Reid, 1972 (Stein, 1964; Glowinski and Axelrod, 1965; Randrup and Munkvad, 1970) .
Dextroamphetamine and levoamphetamine in low doses will release dopamine and noradrenaline from neurones containing these catecholamines (Carlsson, 1970) . D-amphetamine is more potent in this respect, as well as inhibiting dopamine reuptake in striatal dopaminergic neurones (Harris and Baldessarini, 1973; Thornburg and Moore, 1973) . Amphetamines and levodopa both reverse reserpine akinesia in rodents (Carlsson, 1970 were taking amantadine, 200 or 300 mg daily, and 10, anticholinergic drugs. These were continued unchanged throughout the trial of amphetamines. The daily dosage of levoamphetamine was 50 mg, and dextroamphetamine, 15 mg. These dosages were decided on the basis of previous experience in patients with narcolepsy in which they produced increased alertness with few side-effects (Parkes et al., 1974) . DESIGN OF TRIAL Each patient was given either amphetamine or placebo capsules for two weeks followed by the alternative preparation for a further two weeks. Random allocation to the treatment period was made. Levoamphetamine was given twice daily, 30 mg at 8 a.m. and 20 mg at 12 midday in capsules identical in appearance with those containing placebo. Twelve patients who had not developed any side-effects on either levoamphetamine or placebo were given dextroamphetamine, 10 mg at 8 a.m. and 5 mg at 12 midday, for a further two week 2.4 ± 0.6 2.4 ± 0.8 2.8 ± 0.6 8.1 ± 0.9 Placebo 27.8 ± 3.8 1.9 ±0.4 2.6± 0.6 2.7 ± 0.6 6.6 ± 0.9
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Mean systolic and diastolic blood pressures at the start of the trial were 137 and 88 mmHg respectively: on placebo, 132 and 81; on levoed a considerable improvement with levo-amphetamine 128 and 80; and on dextroietamine, while the four least disabled did amphetamine, 135 and 85 mmHg. not respond. The relationship between initial disability and amphetamine response, is shown in Fig. 2 (in the case of levoamphetamine, r=0.6, P <0.01). The patients with a previous thalamolysis all responded to levoamphetamine. The result of treatment did not show a significant relationship with the patient's age, sex, or duration of disease. The patient with post-encephalitic Parkinsonism had a slight reduction in total disability score while on levoamphetamine (28%) and oculogyric crises did not occur on this medication. Nine of 12 patients given dextroamphetamine had a reduction of total disability score on this treatment as compared with placebo, and all but one of these patients responded to both dextro-and levoamphetamine. (Solomon et al., 1937) , although some patients showed a slight lessening of rigidity comparable with that produced separately by anticholinergic drugs. The combination of these with benzedrine resulted in considerable subjective improvement in most patients. Similar results were described by Davis and Stewart (1938 (Halliday and Nathan, 1961) .
SIDE-EFFECTS
The failure of amphetamines to produce much improvement in Parkinson's disease may be due to the fact that these drugs cause the release of endogenous neuronal catecholamines, as well as blockade of catecholamine re-uptake. Both these effects depend on neuronal stores of dopamine, known to be depleted in Parkinson's disease. Levodopa in contrast appears to be converted to dopamine largely by extraneuronal aromatic acid decarboxylase, and dopamine may have a direct post-synaptic effect in the striatum in spite of degeneration of nigrostriatal dopamine neurones. An increase in cerebral dopamine synthesis as the result of levodopa treatment may be necessary in patients with Parkinson's disease before an additional effect of amphetamines is apparent; patients on levodopa had the greatest benefit from amphetamines in the present trial. Amphetamines have no effect in reversing reserpine akinesia in animals who are also treated with alpha-methyl-para-tyrosine, a drug which prevents the synthesis of catecholamines. However, the activity of D-amphetamine may be restored by a very small dose of dopa which is ineffective per se (Carlsson, 1970) .
Choreiform and other movements are common side-effects of levodopa treatment but are rarely produced by amphetamines, although orofacial movements, tics, and seemingly compulsive motor behaviour may occur in amphetamine addicts as well as in hyperkinetic children on chronic high amphetamine dosage (Ashcroft et al., 1965; Mattson and Calverley, 1968; Rylander, 1972) . This difference may be related to the different diseases treated, and to a greater effect of levodopa than amphetamines on cerebral dopamine systems. Amphetamines increased levodopa-induced movements in two patients. Nausea and vomiting may occur during initial treatment in most patients given levodopa but are less common side-effects of amphetamine, although both drugs cause anorexia. The central stimulant effects of amphetamines, in particular insomnia and jitteriness, do not occur to the same extent with levodopa. Stimulant effects may be partially due to potentiation of central noradrenaline, rather than dopamine, mechanisms by amphetamines (Stein, 1964) , whereas levodopa has little effect on cerebral noradrenaline concentration (Everett and Borcherding, 1970) .
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